TICKERNERD
Menu
LONAHealthcare · Biotechnology

LONA Stock Forecast: LeonaBio, Inc. Price Predictions for 2026-2027

Last close, 20 Aug 2026
$7.70
−1.66% on the day

The 4 Wall Street analysts covering LeonaBio, Inc. hold a median 12-month price target of $17 — +120.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$72.4M
Ticker Nerd rank
44 / 100
Median analyst target
$17
Analysts covering
4
Total return, dividends reinvested
1W
−2.2%
1M
+1.7%
YTD
+1.7%
1Y
+93.0%
From 52W high
−34.1%
From 52W low
+113.9%
$4
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LONA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LeonaBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Size
79
Momentum
71
Revisions
58
Volatility
44
Issuance
38
Value
24
Growth
22
Quality
18

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LONA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LONA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26LONAHigh $20Median $17Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $15Median $17High $20

The green dot is the last close — the median target sits +120.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
19 Aug 2026MizuhoMaintainsOutperform$16 → $15
17 Aug 2026CitizensMaintainsMarket Outperform$18 → $17
30 July 2026CitizensUpgradeMarket Outperform$18
30 July 2026CitizensUpgradeMarket Outperform—
27 May 2026Piper SandlerInitiatesOverweight$20
27 May 2026Piper SandlerInitiatesOverweight—
19 Feb 2026MizuhoUpgradeOutperform—
19 Sept 2024MizuhoDowngradeNeutral$5.00 → $0.50
4 Sept 2024BTIGDowngradeNeutral—
4 Sept 2024JMP SecuritiesDowngradeMarket Perform—
19 Aug 2024Rodman & RenshawInitiatesBuy$22
20 June 2024JMP SecuritiesReiteratesMarket Outperform$19
16 May 2024JMP SecuritiesReiteratesMarket Outperform$19
11 Aug 2023JMP SecuritiesMaintainsOutperform$20 → $19
15 May 2023MizuhoMaintainsBuy$6.00 → $5.00
30 Mar 2023BTIGMaintainsBuy$33 → $10
24 Mar 2023JMP SecuritiesReiteratesMarket Outperform$20
7 July 2022MizuhoInitiatesBuy$6.00
23 June 2022JefferiesDowngradeHold$32 → $3.00
23 June 2022JMP SecuritiesDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LONA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LONA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

LeonaBio, Inc. (LONA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 45% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−431.4%

Higher than 3% of US stocks

Return on assets
−74.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LONA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LONALeonaBio, Inc.$72.4M
44
PLRXPliant Therapeutics, Inc.$71.5M
66
IBIOiBio, Inc.$71.0M
26
OSTXOS Therapies, Inc.$70.8M
29
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
SERSerina Therapeutics, Inc.$72.9M
18
RNTXRein Therapeutics, Inc.$70.0M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LeonaBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LONA news & analysis

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

LeonaBio reported its second quarter 2026 financial results and provided a business update, noting it remains on track to complete enrollment of the Phase 3 ELAINE-3 clinical trial of lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer in the fourth quarter of 2026, with topline data expected in the second half of 2027.

Why it matters — A LONA watcher would care because the ELAINE-3 trial timeline represents the company's key late-stage pipeline milestone, and the updated guidance signals continued progress toward a potential regulatory catalyst.

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer

GlobeNewsWire · 12 Aug 2026positive

LeonaBio, Inc. announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's 4th Summit on Breast Cancer, held August 18–22, 2026, in Kona, Hawaii. The presentations relate to lasofoxifene's use in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

Why it matters — A LONA watcher would care because this gives the company's lead candidate, lasofoxifene, increased clinical visibility and presentation slots at a specialty breast-cancer conference.

FAQ

Frequently asked questions about LONA stock

What is the LONA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering LeonaBio, Inc. have a median 12-month price target of $17, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LONA stock a buy right now?

Of the 4 analysts covering LeonaBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeonaBio, Inc. 44 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LONA?

As at 22 Aug 2026, LeonaBio, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will LONA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +120.8% from the last close, and Ticker Nerd's factor model ranks LeonaBio, Inc. 44 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LONA stock forecast for 2030?

No analyst covering LeonaBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LONA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has LONA stock performed over the past year?

LeonaBio, Inc. returned +93.0% over the 12 months to 20 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LeonaBio, Inc. do?

Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases.

What is the latest news on LONA?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update". LeonaBio reported its second quarter 2026 financial results and provided a business update, noting it remains on track to complete enrollment of the Phase 3 ELAINE-3 clinical trial of lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer in the fourth quarter of 2026, with topline data expected in the second half of 2027.

Company

About LeonaBio, Inc.

Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company's primary aim is to discover and commercialize novel therapeutics targeting Alzheimer's disease and other neurological disorders. Athira Pharma's lead product candidate is designed to help repair neuronal damage, potentially offering a regenerative approach to these debilitating conditions. The company employs cutting-edge research in protein therapeutics and uses proprietary small molecule therapeutics to improve cognitive function by targeting mechanisms that facilitate neural health and maintenance. Based in the biopharmaceutical innovation hub of the United States, Athira Pharma plays a significant role in the biotech sector, particularly in the neurology and Alzheimer's treatment market. It operates within a crucial segment of the healthcare industry, addressing some of the most challenging and urgent unmet medical needs. The company's initiatives, driven by scientific research and development, underline its commitment to transforming the treatment landscape for neurodegenerative diseases, contributing to the broader goals of the healthcare and life sciences industries.

CEO Dr. Mark J. Litton M.B.A., Ph.D. · 19 employees · United States · https://www.leonabio.com